Repression of Farnesoid X Receptor during the Acute Phase Response*

Min Sun Kim, Judy Shigenaga, Art Moser, Kenneth Feingold, and Carl GrunfeldDagger

From the Department of Medicine, University of California San Francisco, Metabolism Section, Medical Service, Department of Veterans Affairs Medical Center, San Francisco, California 94121

Received for publication, December 11, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The acute phase response is associated with changes in the hepatic expression of genes involved in lipid metabolism. Nuclear hormone receptors that heterodimerize with retinoid X receptor (RXR), such as thyroid receptors, peroxisome proliferator-activated receptors, and liver X receptors, modulate lipid metabolism. We recently demonstrated that these nuclear hormone receptors are repressed during the acute phase response induced by lipopolysaccharide (LPS), consistent with the known decreases in genes that they regulate. In the present study, we show that LPS significantly decreases farnesoid X receptor (FXR) mRNA in mouse liver as early as 8 h after LPS administration, and this decrease was dose-dependent with the half-maximal effect observed at 0.5 µg/100 g of body weight. Gel-shift experiments demonstrated that DNA binding activity to an FXR response element (IR1) is significantly reduced by LPS treatment. Supershift experiments demonstrated that the shifted protein-DNA complex contains FXR and RXR. Furthermore, the expression of FXR target genes, SHP and apoCII, were significantly reduced by LPS (70 and 60%, respectively). Also, LPS decreases hepatic LRH expression in mouse, which may explain the reduced expression of CYP7A1 in the face of SHP repression. In Hep3B human hepatoma cells, both tumor necrosis factor (TNF) and interleukin-1 (IL-1) significantly decreased FXR mRNA, whereas IL-6 did not have any effect. TNF and IL-1 also decreased the DNA binding activity to an IR1 response element and the expression of SHP and apoCII. Importantly, TNF and IL-1 almost completely blocked the expression of luciferase activity linked to a FXR response element promoter construct transfected into Hep3B cells. Together with our earlier studies on the repression of RXRs, peroxisome proliferator-activated receptors, LXRs, thyroid receptors, constitutive androstane receptor, and pregnane X receptor, these results suggest that decreases in nuclear hormone receptors are major contributors to the decreased gene expression that occurs in the negative acute phase response.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The acute phase response (APR)1 is induced during infection, inflammation, and injury and is associated with a wide range of metabolic changes (1). Among these, changes in lipid metabolism have received much attention due to the link between infection/inflammatory diseases and atherosclerosis (2-6). The characteristic changes in lipid metabolism during the APR include hypertriglyceridemia (7), decreases in serum high density lipoprotein cholesterol levels (8, 9), increased hepatic cholesterol synthesis, inhibition of bile acid synthesis (10), increased hepatic fatty acid synthesis, and decreased hepatic fatty acid oxidation and ketogenesis (11, 12). These changes are mediated by alterations in gene expression caused by pro-inflammatory cytokines including TNFalpha , IL-1beta , and IL-6 (10). However, the underlying mechanism by which these cytokines regulate gene transcription is not well understood, especially for the negative acute phase proteins.

Nuclear hormone receptors are ligand-activated transcription factors that are involved in various biological processes including development and physiological homeostasis (13). Small lipophilic molecules such as steroids, thyroid hormones, vitamin D, and retinoids bind to and activate these receptors to exert their physiological effects by regulating the transcription of specific genes (13-15). These receptors share common structural features, including central, highly conserved DNA binding domains and carboxyl-terminal ligand binding domains (13-15). They can be divided into four major subgroups based on their dimerization and DNA binding properties. Type II receptors are characterized by their DNA binding as a heterodimer with the 9-cis-retinoic acid receptor (RXR) (13, 16). This group includes the peroxisome proliferator-activated receptor (PPAR), retinoic acid receptor, vitamin D receptor, liver X receptor (LXR), and thyroid hormone receptors (TRs) (13, 17).

The farnesoid X receptor (FXR) was once an orphan receptor, and recently, it was found that bile acids are the ligands for FXR (18-20). FXR forms an obligate heterodimer with RXR and, thus, belongs to the Type II nuclear receptor subgroup. FXR has been shown to bind to FXR response elements (FXRE) composed of two inverted hexanucleotide repeats (AGGTCA) spaced by one nucleotide (IR-1) (21). Chenodeoxycholic acid (CDCA), the most potent ligand for FXR, induces the ileal bile acid-binding protein (I-BABP) (18, 22), bile salt export pump (23), phospholipid transfer protein (PLTP) (21, 24), apolipoprotein CII (apoCII) (25), and SHP (26).

Activation of FXR down-regulates the expression of CYP7A1 via the action of SHP protein (26). FXR-induced SHP binds to and inactivates the liver receptor homolog 1(LRH), a transcription factor that is required for the expression of cholesterol 7alpha -hydroxylase (CYP7A1) (26, 27). CYP7A1 is a rate-limiting enzyme in the neutral pathway of bile acid synthesis (28), and therefore, FXR activation inhibits bile acid biosynthesis. Because bile acid is synthesized from cholesterol in the liver and is the major route for the elimination of cholesterol from the body, regulation of CYP7A1 transcription and activity indicates a critical role of FXR in the regulation of cholesterol metabolism.

A number of genes involved in lipid metabolism whose hepatic expression is decreased during the acute phase response are known to be regulated by type II nuclear hormone receptors. Previously, we demonstrated that in Syrian hamsters, LPS administration results in a decrease in hepatic mRNA and/or protein levels of RXRalpha , -beta , and -gamma , PPARalpha and -gamma , TRalpha and -beta , and LXRalpha (29, 30). Furthermore, hepatic nuclear extracts obtained from animals treated with LPS exhibited a reduced binding activity to RXR-RXR, RXR-PPAR, RXR-TR, and RXR-LXR response elements (29, 30). This suggests that reduced hepatic RXR levels alone or in combination with decreases in PPARs and LXR could be a mechanism for coordinately inhibiting the expression of multiple genes during the acute phase response.

Expression of two proteins that are regulated by FXR, bile salt export pump (BSEP) (31) and phospholipid transfer protein (PLTP) (32), are decreased during the APR. Therefore, we hypothesized that the bile acid receptor FXR is also suppressed during APR, affecting lipid/cholesterol metabolism. In the present study, we demonstrate that LPS and pro-inflammatory cytokines TNFalpha and IL-1beta decrease the expression of FXR, its DNA binding activity to FXR response element (IR1), and transcription by FXR in studies of mice in vivo and the Hep3B human hepatoma cells in vitro, which is accompanied by decreased expression of FXR-regulated genes, SHP, and apoCII. The data suggest that altered FXR activity may contribute to the changes in lipid and cholesterol metabolism that occur during the APR.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- LPS (Escherichia coli 55:B5) was obtained from Difco and freshly diluted to the desired concentration in pyrogen-free 0.9% saline. Minimum essential medium (MEM) was purchased from Fisher. Cytokines (human TNFalpha , human IL-1beta , and human IL-6) were from R&D Systems and were freshly diluted to desired concentrations in serum-free MEM media containing 0.1% bovine serum albumin (fatty acid-free). Tri-Reagent and fatty acid-free bovine serum albumin were from Sigma. [alpha -32P]dCTP (3,000 Ci/mmol) and [gamma -32P]dATP (3,000 Ci/mmol) were purchased from PerkinElmer Life Sciences. Oligo(dT)-cellulose type 77F was from Amersham Biosciences.

Animals-- Eight-week-old female C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The animals were maintained in a normal light-cycle room and were provided with rodent chow and water ad libitum. Anesthesia was induced with halothane. To determine the effect of APR on FXR and other mRNA levels, mice were injected IP with 100 µg of LPS in saline or with saline alone. Food was withdrawn at the time of injection, because LPS induces anorexia in rodents (33). Livers were removed at the time indicated in the figure legends (Figs. 1, 2, 4) after treatment. The doses of LPS used in this study have significant effects on triglyceride and cholesterol metabolism (7) but are not lethal because the LD50 for LPS in rodents is ~5 mg/100 g of body weight.

Cell Culture-- Hep3B cells were maintained in MEM medium supplemented with 10% fetal bovine serum in 75-cm2 flasks. Cells were washed twice with phosphate-buffered saline (Ca2+- and Mg2+-free) and trypsinized before seeding. For typical experiments, cells were seeded in 100-mm dishes at a concentration of 2 × 106 cells/dish. After an overnight incubation, cells were washed twice with phosphate-buffered saline, and medium was replaced with fresh MEM (without serum) plus 0.1% bovine albumin and the appropriate cytokine concentration. For transfection assays, 1.5 × 105 cells were used/well in 6-well plates.

RNA Isolation and Northern Blot Analysis-- Total RNA from mouse was isolated from 300-400 mg of snap-frozen whole liver and ~100 mg of kidney tissue using Tri-Reagent (Sigma). Poly(A)+ RNA was subsequently purified using oligo(dT) cellulose. RNA was quantified by measuring absorption at 260 nm. 10 µg of poly(A)+ were denatured and electrophoresed on a 1% agarose, formaldehyde gel. Total RNA from Hep3B was isolated from a 100-mm dish by the Tri-Reagent method and resuspended in diethyl pyrocarbonate-treated water. 30 µg of total RNA was denatured and electrophoresed as described above. The uniformity of sample loading was checked by UV visualization of the ethidium bromide-stained gel before electrotransfer to Nytran membrane (Schleicher & Schuell). Prehybridization, hybridization, and washing procedures were performed as described previously (34). Membranes were probed with [alpha -32P]dCTP-labeled cDNAs using the random priming technique (Amersham Biosciences). mRNA levels were detected by exposure of the membrane to x-ray film and quantified by densitometry. Glyceraldehyde-3-phosphate dehydrogenase was used as a control probe. LRH-1 cDNA was kindly provided by Dr. Kristina Schoonjans (Institut de Genetique et de Moleculaire et Cellulaire, Universite Louis Pasteur, Paris, France). Mouse and human FXR, SHP, and apoCII probes were prepared by PCR using the following primers: FXR 5'-CGT GAC TTG CGN CAA GTG ACC-3' (upper), 5'-CCA NGA CAT CAG CAT CTC AGC-3' (lower); SHP 5'-AGG GGT CTG CCC ATG CCA G-3' (upper), 5'-GGT CAC CTC AGC AAA AGC ATG TC-3' (lower); apoCII 5'-GCC AAG GAG GTT GCC AAA G-3' (upper), 5'-GGT CTG GTG ATG CGA GCA A-3' (lower).

Preparation of Nuclear Extracts-- Nuclear extracts were prepared according to Neish et al. (35). Briefly, cells were disrupted in a sucrose-HEPES buffer containing 0.5% Nonidet-P40 as a detergent, protease inhibitors, and dithiothreitol. After disruption by 5 min of incubation on ice and centrifugation, nuclear proteins were separated in a NaCl-HEPES buffer and re-suspended in a glycerol-containing buffer. All the procedures were carried out on ice. Protein quantification was determined by the Bradford assay (Bio-Rad), and yields were similar in control and cytokine-treated groups.

Electromobility Shift Assay-- 10 µg of crude nuclear extract were incubated on ice for 30 min with 6 × 104 cpm of 32P-labeled oligonucleotides in 15 µl of binding buffer consisting of 20% glycerol, 25 mM Tris-HCl, pH 7.5, 40 mM KCl, 0.5 mM MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol, 2 µg of poly(dI-dC), and 1 µg of salmon sperm DNA. Double-stranded oligonucleotide probes were end-labeled with T4-polynucleotide kinase (Amersham Biosciences) in the presence of 50 µCi of [gamma -32P]dATP and purified on a Sephadex G-25 column (Amersham Biosciences). DNA-protein complexes were separated by electrophoresis (constant voltage of 200 V) on a 5% nondenaturing polyacrylamide gel in 0.5× Tris-buffered EDTA at 4 °C. The gel was dried, exposed to x-ray film, and quantified by densitometry. In the competition assay, a 100-fold molar excess of the specific or mutated unlabeled oligonucleotide was preincubated on ice for 1 h with 10 µg of nuclear extract from control cells. The following oligonucleotides were used: IR1, 5'-GATCGGCCAGGGTGAATAACCTCGGGG-3'; mut-IR1, 5'-GATCGGCCAGGAAGAATATTCTCGGGG-3'.

Transfection Studies-- Hep3B cells were grown overnight in 35-mm plates and washed twice with serum-free medium. DNA-Lipofectin complex containing 1.5 µg/ml FXRE-luciferase vector (a gift from Dr. Mangelsdorf, University of Texas Southwestern Medical Center, Dallas, TX), 0.5 µg/ml Rous sarcoma virus beta -galactosidase vector (a gift from Dr. Allan Pollock, Nephrology section at Veterans Affairs Medical Center, San Francisco, CA), and 5 µg/ml Lipofectin (Invitrogen) were allowed to form at room temperature for 15 min. The cells were overlaid with the DNA-Lipofectin complex and incubated at 37 °C for 4-6 h. After washing the cells with serum-free medium, fresh growth medium containing 10% fetal bovine serum was added.

Enzyme Assay-- Transfected cells were treated with lysis buffer (Promega, Madison, WI), and aliquots of the lysates were assayed for luciferase and beta -galactosidase enzyme activity as described in the manufacturer's instruction using Wallac VICTOR2TM 1420 Multilabel Counter (PerkinElmer Life Sciences). beta -Galactosidase enzyme activity was used to normalize for variability in the transfection efficiency.

Statistical Analysis-- Data are expressed as the mean ±S.E. of experiments from 3-5 animals or plates for each groups or time point. The difference between two experimental groups was analyzed using the Student's t test. Differences among multiple groups were analyzed using one way analysis of variance with the Bonferroni's post hoc. A p value < 0.05 was considered significant.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

LPS Decreases FXR mRNA Level-- We initially determined the effect of LPS administration on the FXR mRNA levels in mouse liver at various times up to 24 h. As shown in Fig. 1A, LPS (100 µg) administration did not cause any significant change in the FXR mRNA level at 2 h. However, FXR mRNA decreased significantly by 8 h to ~40% that of the control level, and the reduction persisted for 24 h. Next, we determined if FXR mRNA decreases in a dose-dependent manner in response to LPS administration. As shown in Fig. 1B, the LPS-induced decrease in FXR mRNA was dose-dependent in mouse liver, with the half-maximal effect occurring at ~0.5 µg/100 g of body weight. All doses tested in the experiment caused a significant reduction in FXR mRNA levels. Thus, LPS decreases FXR mRNA levels in the liver of mice at relatively low doses.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of LPS on FXR expression in mouse. A, time course in liver. C57BL/6 mice were injected IP with either saline or LPS (100 µg of LPS/mouse), and the animals were sacrificed at the time indicated after LPS administration. Poly(A)+ RNA was prepared from liver, and Northern blot analysis was carried out as described under "Experimental Procedures." B, dose response in liver. C57BL/6 mice were injected IP with LPS at various concentrations as indicated, and animals were sacrificed 16 h after LPS administration. C, effect of LPS on FXR expression in the kidney. C57BL/6 mice were injected IP with LPS (100 µg of LPS/mouse), and animals were sacrificed 16 h after LPS administration. Mouse kidney poly(A)+ RNA was prepared, and Northern blot analysis was carried out as described under "Experimental Procedures." Data (means ± S.E., n = 4~5) are expressed as a percentage of controls. *, p < 0.05 versus control.

Because hepatic expression of FXR is down-regulated by LPS administration in mouse liver, next we examined if FXR expression is altered in the intestine and the kidney, which also express FXR. As in the liver, LPS administration for 16 h caused a significant decrease (~55%) in the level of FXR mRNA in the kidney (Fig. 1C). However, FXR mRNA was not reduced in the intestine (~130%), suggesting that LPS causes tissue-specific responses in terms of FXR expression. These results indicate that LPS-induced APR reduces expression of FXR in mouse liver and kidney but not in the intestine.

LPS Administration Decreases the DNA Binding Activity of FXR-- Nuclear hormone receptors exert their effect on transcriptional regulation by binding to their cognitive response element in the promoter region of target genes. To determine whether the reduction of FXR mRNA caused by LPS administration affects the DNA binding activity of FXR, we isolated nuclei from mouse liver and performed the electrophoretic gel mobility shift assay using a 32P-labeled DNA oligonucleotide containing FXR response element IR-1. As shown in Fig. 2A, two major FXR·IR1 complexes were observed in the control samples. LPS administration significantly decreased the binding of proteins in the nuclear extract from mouse liver to IR1 when compared with the control. LPS decreased FXR·IR1 binding by ~75 and ~50% for the upper and the lower band, respectively (Fig. 2B). Competition with 100-fold molar excess of specific oligonucleotide (WT), but not with mutated oligonucleotide (Mut), abolished the complex formation of radiolabeled IR1 with FXR (Fig. 2A), demonstrating the specificity of the two complexes. Furthermore, we demonstrated that the complexes contain FXR and RXR. They were supershifted with anti-FXR (SS1, second lane) and anti-RXR (SS2, third lane) antibody (Fig. 3). The migration of FXR·DNA complex was not affected by nonspecific IgG (fifth lane).


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of LPS treatment on binding of hepatic nuclear extracts to FXR response element IR1. C57BL/6 mice were injected IP with either saline or LPS (100 µg of LPS/mouse). Sixteen hours later, the animals were sacrificed, and hepatic nuclear extracts (NE) were prepared as described under "Experimental Procedures." Ten micrograms of nuclear extracts were incubated with radiolabeled oligonucleotides IR1 representing binding site for FXR. A, a representative electrophoretic gel mobility shift assay. Unlabeled specific (100× WT) and nonspecific (100× Mut) competing oligonucleotides were included at a 100-fold excess 1 h before the addition of the labeled probes. Arrows represent specific IR1-bound complexes. B, densitometric analysis of hepatic DNA-binding proteins. Data (means ± S.E., n = 5) are expressed as a percentage of controls. *, p < 0.05 versus control.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 3.   Protein IR1 complexes contains FXR and RXR. Electrophoretic mobility shift assay was performed using a nuclear extract from a control mouse in the presence of antibodies raised against FXR (lane 2), RXR (lane 3), both FXR and RXR (lane 4), and rabbit IgG (lane 5). SS1 and SS2 represent the complexes supershifted by the FXR and RXR antibodies, respectively.

LPS Administration Reduces mRNA Levels of SHP and ApoCII-- To determine whether the decreased binding of FXR to DNA in hepatic nuclear extracts from LPS-treated mouse is associated with reduced transcription of FXR-regulated genes, we investigated the effect of LPS administration on the mRNA levels of SHP and apoCII, two of genes that are known to be regulated by FXR. SHP is a key mediator of the FXR effect on the transcriptional regulation of CYP7A1 gene, and SHP is induced by FXR activation. As shown in Fig. 4, LPS administration decreases the expression of SHP by ~70% and apoCII by 60% in mouse liver when compared with control. These data demonstrate that FXR-regulated genes are also repressed during LPS-induced APR in the mouse.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of LPS on the expression of FXR target genes SHP and apoCII. Hepatic total RNA was prepared 16 h after saline or LPS administration (100 µg of LPS/mouse) from mouse liver. Northern blot analysis was performed as described under "Experimental Procedures" using SHP and apoCII cDNAs. Data (means ± S.E., n = 4~5) are expressed as a percentage of controls. *, p < 0.05 versus control.

LRH Expression Decreases during APR-- It is well established that FXR down-regulates CYP7A1 expression as a feedback mechanism to maintain homeostasis of bile acid metabolism (26, 27). This is achieved by FXR-induced stimulation of SHP expression (26). SHP binds to and inactivates LRH, which is required for the transcriptional activation of CYP7A1 (26). Therefore, based on the above results showing a decrease in FXR and SHP, it is reasonable to expect an increase in the level of CYP7A1 during the APR. However, our previous studies demonstrated that the expression of Cyp7A1 is down-regulated during the APR induced by LPS administration in vivo (36). Thus, we determined the effect of LPS on the expression of LRH in mouse liver. As shown in Fig. 5, LPS administration for 16 h caused an ~65% reduction in the LRH mRNA levels in mouse liver. This result suggests that the LPS-induced decrease in LRH may play a major role in determining the transcriptional regulation of CYP7A1.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 5.   LPS administration decreases the expression of LRH in mouse liver. Hepatic total RNA was prepared 16 h after saline or LPS administration (100 µg of LPS/mouse) from mouse liver. Northern blot analysis was performed as described under "Experimental Procedures." Data (means ± S.E., n = 4~5) are expressed as a percentage of controls. *, p < 0.05 versus control.

TNF and IL-1, but Not IL-6, Decrease FXR mRNA in Hep3B Human Hepatoma Cells-- It is well known that the physiological effect of LPS is mediated by pro-inflammatory cytokines such as TNF, IL-1, and IL-6. To determine whether these cytokines also decrease FXR mRNA in vitro, as LPS does in mouse liver, human hepatoma cell line Hep3B cells were treated with cytokines at 10 ng/ml for 24 h, and RNA was isolated for Northern analysis. As shown in Fig. 6, TNF treatment decreased FXR mRNA to less than 20% that of the control level. Also, IL-1 decreased FXR mRNA by 60%. However, IL-6 did not affect FXR expression in Hep3B cells (data not shown). These results suggest that the effect of LPS on FXR expression is mediated by TNF and IL-1.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 6.   Regulation of FXR expression by TNF and IL-1 in Hep3B human hepatoma cells. ~7 × 105 Hep3B cells were plated in 100-mm Petri dishes in culture media containing 10% serum. After an overnight incubation, cells were washed twice with phosphate-buffered saline, and medium was replaced with fresh MEM (without serum) plus 0.1% bovine albumin and the appropriate cytokine at 10 ng/ml. After 24 h of incubation, total RNA was isolated, and Northern blot analysis was performed as described under "Experimental Procedures." Data (means ± S.E., n = 3) are expressed as a percentage of controls. *, p < 0.05 versus control.

TNF Reduces the DNA Binding Activity of FXR in Hep3B Cells-- Because the inflammatory cytokine TNF causes a reduction in the FXR mRNA, we next determined if TNF also causes a similar change in the DNA binding activity of nuclear extracts from human hepatoma cells to an IR-1 FXR response element. For this experiment, Hep3B cells were treated with TNF at 10 ng/ml. After 24 h the nuclei were isolated, and an electromobility shift assay was conducted as described under "Experimental Procedures." As shown in Fig. 7A, TNF treatment at 10 ng/ml in Hep3B cells reduced the binding of FXR to IR1, confirming the in vivo result. The reduction of DNA binding activity was ~75 and ~55% that for the upper and the lower band, respectively (Fig. 7B). Competition with 100-fold molar excess of IR1 oligonucleotide (WT), but not of mutated oligonucleotide (Mut), abolished the shift of DNA band (Fig. 7A), indicating the complex specificity. Furthermore, the FXR·DNA complex showed supershifting after incubation of control nuclear extract with anti-FXR antibodies (Fig. 8). These results indicate that the decrease in FXR expression is associated with a decline in the DNA binding activity of FXR during the acute phase caused by the proinflammatory cytokine TNF in Hep3B cells.


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of LPS treatment on binding of Hep3B cell nuclear extracts to FXR response element IR1. Hep3B cells were treated with either vehicle or TNF at 10 ng/ml for 24 h, and hepatic nuclear extracts (NE) were prepared as described under "Experimental Procedures." Ten micrograms of nuclear extracts were incubated with radiolabeled oligonucleotides IR1 representing binding site for FXR. A, a representative electrophoretic gel mobility shift assay. Unlabeled specific (100× WT) and nonspecific (100× Mut) competing oligonucleotides were included at 100-fold excess 1 h before the addition of the labeled probes. Arrows represent specific IR1-bound complexes. B, densitometric analysis of DNA-binding proteins. Data (means ± S.E., n = 4) are expressed as a percentage of controls. *, p < 0.05 versus control.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 8.   Protein binding to IR1 contains FXR. Electrophoretic mobility shift assay was performed as described under "Experimental Procedures" using a nuclear extract from a vehicle-treated Hep3B cells in the absence (lane 1) or presence of antibody raised against FXR (lane 2). Arrows indicate the complexes supershifted by the FXR antibody.

TNF and IL-1 Decrease the Expression of FXR-regulated Genes SHP and ApoCII-- We next examined if the expression levels of two genes that are known to be regulated by FXR are also affected by TNF and IL-1 in Hep3B human hepatoma cells. Treatment of Hep3B cells with TNF and IL-1 at 10 ng/ml for 24 h decreased SHP mRNA level by ~60 and ~50%, respectively (Fig. 9A). Likewise, both TNF and IL-1 significantly decrease apoCII mRNA by 65 and 57%, respectively. Furthermore, TNF also inhibited CDCA-stimulated expression of apoCII (Fig. 9B). These results demonstrate that TNF and IL-1 decrease both the basal and stimulated expression of FXR-regulated target genes in Hep3B human hepatoma cells.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 9.   TNF and IL-1 suppress the expression of FXR target genes SHP and apoCII. A, TNF and IL-1 inhibit the basal expression of SHP and apoCII in human hepatoma cells. Hep3B cells were cultured for 24 h with vehicle or cytokine treatment (10 ng/ml) as indicated in the figure. Total RNA was prepared, and Northern blot analysis was performed as described under "Experimental Procedures." Data (means ± S.E., n = 3) are expressed as a percentage of controls. *, p < 0.05 versus control. B, inhibition of CDCA-stimulated apoCII expression by TNF and IL-1. Hep3B cells were cultured in the vehicle (Control) or 50 µM CDCA alone or with TNF (CDCA + TNF), and apoCII mRNA was measured as described above. Data (means ± S.E., n = 3) are expressed as a percentage of controls. a, p < 0.05 versus control; b, p < 0.05 versus CDCA.

Inhibition of FXRE-Luciferase Activity by TNF and IL-1-- To further elucidate the effect of cytokine treatment on the expression of genes regulated by FXR, we next carried out the transfection studies using a FXRE construct linked to luciferase. The FXRE-Luc construct contains five copies of FXR response element with basal promoter activity. Luciferase activity was not observed in the absence of FXR stimulation. Therefore, basal luciferase activity was stimulated with a natural ligand of FXR, chenodeoxycholic acid. As shown in Fig. 10, both TNF and IL-1 almost completely abolished the activity of luciferase linked to FXRE when compared with control. This result clearly demonstrates that TNF and IL-1 treatment of Hep3B cells inhibits the expression of FXRE-regulated genes.


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 10.   Inhibition of FXRE-luciferase activity by TNF and IL-1. Hep3B cells were plated in 6-well plates (1.5 × 105) the day before transfection in MEM media supplemented with 10% fetal bovine serum. Transient transfections were performed as described under "Experimental Procedures." The next day cells were washed twice with serum-free media, and the basal luciferase activity was stimulated by incubating cells in CDCA-containing media supplemented with 0.1% bovine serum albumin. After 30 min, cells were treated with 10 ng/ml TNF or IL-1 as indicated in the figure using the serum-free media supplemented with 0.1% bovine serum albumin and cultured for 24 h. At the end of the incubation, cells were harvested in a lysis buffer, and luciferase and galactosidase activity were determined (Promega). Data (means ± S.E., n = 3) are expressed as a percentage of controls. *, p < 0.05 versus control.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Infection, inflammation, and trauma induce a wide range of metabolic changes in the liver as part of APR and result in the altered concentration of plasma proteins that are collectively called acute phase proteins (1, 37). During the APR, the levels of proteins such as C-reactive protein and serum amyloid A increase (positive acute phase proteins), whereas the levels of proteins such as albumin and transferrin decrease (negative acute phase proteins) (1, 37, 38). It is believed that positive acute phase proteins play a role in protecting the host by neutralizing foreign agents to minimize tissue damage (39). Inflammatory cytokines such as TNF, IL-1, and IL-6 mediate the APR and the transcriptional regulation of positive and negative acute phase proteins. Activation of the TNF/IL-1 receptors stimulates membrane sphingomyelinase to convert sphingomyelin to ceramide, which leads to the activation and translocation of transcription factors activator protein-1 and nuclear factor kappa B and induces class I acute phase proteins (40, 41). On the other hand, activation of the IL-6 receptor activates Janus tyrosine kinase and subsequently phosphorylates tyrosine residue of signal transducer and activator of transcription proteins, inducing transcription of class II proteins (41, 42).

The mechanisms regulating the negative acute phase proteins are not as well understood. Recently, our studies together with others showed that several nuclear hormone receptors including HNF-4, RXRs, retinoic acid receptors, LXRs, PPARs, TR, constitutive androstane receptor, and pregnane X receptor are down-regulated in the liver during the APR (29, 30, 43, 44) and suggested that they might be involved in the repression of several negative acute phase proteins. For example, a decrease in PPARalpha may contribute to the reduced expression of acyl-CoA synthetase (29, 34) and carnitine palmitoyltransferase I (45) during the APR. Similarly, a decrease in LXR, LRH, and SHP may contribute to the decrease in cholesteryl ester transfer protein (46). Because many of the proteins regulated by nuclear hormone receptors are involved in the metabolism of triglyceride, cholesterol, and bile acids, it is likely that repression of key nuclear receptors during the APR may be one of the mechanisms accounting for the changes in lipid metabolism.

In the present study, we show that the induction of the APR by LPS administration decreases the level of FXR mRNA in mouse liver. The decrease of FXR mRNA was significant as early as ~8 h after LPS administration. Comparing this to our previous study, which showed that RXR protein levels were significantly decreased as early as 2 h (29), the decrease of FXR mRNA is preceded by the repression of RXR. We also investigated the level of FXR mRNA in the kidney and the intestine, two other organs involved in bile acid metabolism. Interestingly, FXR mRNA expression was also down-regulated in the kidney but not in the intestine, indicating that the response of FXR mRNA to LPS is tissue-specific. In the liver, FXR mRNA is decreased by low doses of LPS (the half-maximal dose for FXR mRNA was ~0.5 µg/100g of body weight), indicating that the reduction in FXR mRNA is a highly sensitive response to LPS. Furthermore, in vitro experiments with Hep3B cells show that TNF and IL-1, but not IL6, decreased the level of FXR mRNA, suggesting that the decrease of FXR mRNA by LPS in mouse liver is mediated by the action of the inflammatory cytokines TNF and IL-1.

The decrease in FXR mRNA levels in the liver during the APR may influence the transcription of its target genes. Our study shows that FXR binding to FXR response element IR1 is decreased after LPS and cytokine treatment in the nuclear extract from mouse liver and Hep3B cells, respectively. In the electromobility shift assay, we were able to observe two bands that were shifted from the unbound free probe, and both bands were supershifted by the FXR antibody. The presence of two bands could result from the presence of other proteins such as RXR, coactivators, and/or corepressors. Also, the supershift experiment confirms that RXR is a partner of FXR.

The decrease of FXR binding to the response element could result in the reduced transcription of target genes such as I-BABP (ileal bile acid-binding protein) (22), BSEP (23), PLTP (21, 24), and apoCII (25). For example, the hepatic expression of BSEP, one of the FXR target genes, has been reported to be down-regulated by LPS, IL-1, and TNF administration (31). Also, Jiang and Bruce (32) report that LPS administration decreased plasma activity of PLTP and its mRNA level in the liver by ~66%. Transfection experiment in the present study clearly demonstrates that TNF and IL-1 almost completely block FXRE-linked luciferase activity, consistent with the decreased expression of FXR target genes by TNF and IL-1. These results agree with our finding that apoCII mRNA level is down-regulated by LPS in mouse liver and by TNF and IL-1 in Hep3B human hepatoma cells. ApoCII mRNA was reduced by ~60%, which is comparable with the changes in PLTP and BSEP.

A decrease in the expression of FXR target genes may provide an explanation for some of the changes in the lipid metabolism during the APR. For example, APR-induced down-regulation of PLTP may disturb the transfer of phospholipids and cholesterol from TG-rich lipoproteins to high density lipoprotein and contribute to the increase of low density lipoproteins. In the present study, we show that expression of apoCII is decreased during the APR. ApoCII is a surface component of chylomicrons, very low density lipoproteins, and high density lipoproteins and plays an important role in plasma lipid metabolism as an activator of lipoprotein lipase (47). Indeed, apoCII deficiency has been linked to the increased plasma levels of triglycerides (48). Therefore, lower apoCII expression during by the APR may contribute to the increased levels of plasma triglycerides that occur during the APR.

Altered expression of FXR target genes during the APR could also affect bile acid synthesis and metabolism. When the high levels of bile acids accumulate in the body, FXR is activated by its natural ligands and negatively regulates the transcription of cholesterol 7alpha -hydroxylase (CYP7A1) as a compensatory mechanism (27, 28). This negative regulation by FXR is mediated by the induction of SHP, an orphan nuclear receptor that inhibits LRH activation of CYP7A1 expression (26). Our present study shows that FXR repression resulted in the reduced level of SHP during the APR, which could theoretically lead to increased levels of CYP7A1 during the APR. However, our previous work demonstrated that CYP7A1 is down-regulated during the LPS-induced APR in Syrian hamsters (36). There are a number of possible explanations for the decrease in CYP7A1. First, we showed that the level of LRH (mouse homologue of CYP7A promoter-binding factor), a nuclear hormone receptor that is required for the transcription of CYP7A1, is also decreased during the APR; a decrease in LRH would decrease the transcription level of CYP7A1 despite a reduction in SHP. Little is known about the transcriptional regulation of LRH, and more studies need to be conducted to further understand the implications of altered expression of LRH during the APR. A second mechanism is that CYP7A1 is regulated by other nuclear hormone receptors including HNF-4 (49, 50), chicken ovalbumin upstream promoter-transcription factor II (50, 51), RXR (51), and LXRalpha (52, 53). Transcription of CYP7A1 is induced by transfection with HNF-4 alone in HepG2 cells and chicken ovalbumin upstream promoter-transcription factor II cotransfection with HNF-4 had a synergistic effect (50). RXRs bind to a DR1 motif in the promoter region and transactivate gene transcription (51). In rats and mouse, LXR is activated in response to oxysterols and induces CYP7A1 transcription to facilitate the excretion of excess cholesterol from the body in the form of bile acids (52, 53). We and others demonstrate that RXR, LXR, and HNF-4 are decreased during the APR (29, 45), conferring limitations on the amount of the transcriptional activators for CYP7A1. A recent report on repression of CYP7A1 by TNF via the HNF-4 site in the bile acid response element also supports the idea of HNF-4 being another key player in the transcriptional regulation of CYP7A1 (54). Finally, repression of CYP7A1 expression by high levels of bile acids, but not by FXR ligands, in SHP-null mice suggests that alternative mechanisms exist for the feedback regulation of CYP7A1 besides FXR/SHP pathway (55). Taken together with other studies (56, 57) that suggest redundant regulatory system for bile acid biosynthesis, it is, thus, not surprising that decreased levels of SHP would not necessarily result in the increased expression of CYP7A1 during the APR in the face of independent decreases in LRH, HNF-4, LXRs, and RXRs.

The effects of LPS are mediated by its stimulation of various immune cells to synthesize and secrete cytokines including TNF, IL-1, and IL-6 (1). TNF, IL-1, and IL-6 have all been shown to play important roles in regulating the increased expression of positive APR proteins. However, in our studies in which TNF and IL-1 inhibit the expression of nuclear hormone receptors, IL-6 does not have any effect (58). Similarly in the present study, TNF and IL-1 caused a decrease in the mRNA levels of FXR and SHP, whereas IL-6 did not have any significant effect. The results suggest that TNF and IL-1 are major mediators for the negative regulation of nuclear hormone receptors and that IL-6 is not involved in this process.

In summary, the present study demonstrates that LPS causes a marked decrease in FXR mRNA and activity in mouse liver. This was associated with reduced expression of FXR target genes SHP and apoCII. Furthermore, cytokines TNF and IL-1 caused a similar decrease in FXR expression, DNA binding activity, transcription, and target genes in Hep3B cells. Coupled with previous studies on the repression of RXRs, retinoic acid receptors, PPARs, LXRs, TR, constitutive androstane receptor, and pregnane X receptor, the results with FXR suggest that decreases in type II nuclear hormone receptors are major contributors to the negative APR. Considering the crucial physiological role of FXR in the feedback regulation on bile acid synthetic pathway and in the metabolism of cholesterol and lipoproteins, our study helps us to understand the underlying mechanisms of the changes in lipid metabolism during the APR.

    FOOTNOTES

* This work was supported by grants from the Research Service of the Department of Veterans Affairs and by National Institutes of Health Grants DK 49448 and AR 39639.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Metabolism Section (111F), Dept. of Veterans Affairs Medical Center, 4150 Clement St., San Francisco, CA 94121. Tel.: 415-750-2005; Fax: 415-750-6927; E-mail: grunfld@itsa.ucsf.edu.

Published, JBC Papers in Press, January 7, 2003, DOI 10.1074/jbc.M212633200

    ABBREVIATIONS

The abbreviations used are: APR, acute phase response; LPS, lipopolysaccharide; TNF, tumor necrosis factor; IL, interleukin; IR, inverted repeat; FXR, farnesoid X receptor; FXRE, FXR response element; RXR, retinoid X receptor; PPAR, peroxisome proliferator-activated receptor; LXR, liver X receptor; SHP, small heterodimer partner; LRH, liver receptor homolog; TR, thyroid receptor; apoCII, apolipoprotein CII; PLTP, phospholipid transfer protein; BSEP, bile salt export pump; CYP7A1, cholesterol 7alpha -hydroxylase; HNF, hepatocyte nuclear factor; IP, intraperitoneally; CDCA, chenodeoxycholic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Kushner, I. (1982) Ann. N. Y. Acad. Sci. 389, 39-48[Medline] [Order article via Infotrieve]
2. Libby, P., Egan, D., and Skarlatos, S. (1997) Circulation 96, 4095-4103[Free Full Text]
3. Jousilahti, P., Vartiainen, E., Tuomilehto, J., and Puska, P. (1996) Lancet 348, 567-572[CrossRef][Medline] [Order article via Infotrieve]
4. Ridker, P. M., Hennekens, C. H., Buring, J. E., and Rifai, N. (2000) N. Engl. J. Med. 342, 836-843[Abstract/Free Full Text]
5. Koenig, W., Sund, M., Frohlich, M., Fischer, H. G., Lowel, H., Doring, A., Hutchinson, W. L., and Pepys, M. B. (1999) Circulation 99, 237-242[Abstract/Free Full Text]
6. Ridker, P. M., Buring, J. E., Shih, J., Matias, M., and Hennekens, C. H. (1998) Circulation 98, 731-733[Abstract/Free Full Text]
7. Feingold, K. R., Staprans, I., Memon, R. A., Moser, A. H., Shigenaga, J. K., Doerrler, W., Dinarello, C. A., and Grunfeld, C. (1992) J. Lipid Res. 33, 1765-1776[Abstract]
8. Sammalkorpi, K., Valtonen, V., Kerttula, Y., Nikkila, E., and Taskinen, M. R. (1988) Metabolism 37, 859-865[Medline] [Order article via Infotrieve]
9. Grunfeld, C., Pang, M., Doerrler, W., Shigenaga, J. K., Jensen, P., and Feingold, K. R. (1992) J. Clin. Endocrinol. Metab. 74, 1045-1052[Abstract]
10. Hardardottir, I., Grunfeld, C., and Feingold, K. R. (1995) Biochem. Soc. Trans. 23, 1013-1018[Medline] [Order article via Infotrieve]
11. Memon, R. A., Feingold, K. R., Moser, A. H., Doerrler, W., and Grunfeld, C. (1992) Endocrinology 131, 1695-1702[Abstract]
12. Memon, R. A., Feingold, K. R., Moser, A. H., Doerrler, W., Adi, S., Dinarello, C. A., and Grunfeld, C. (1992) Am. J. Physiol. 263, E301-E309[Medline] [Order article via Infotrieve]
13. Mangelsdorf, D. J., and Evans, R. M. (1995) Cell 83, 841-850[Medline] [Order article via Infotrieve]
14. Blumberg, B., and Evans, R. M. (1998) Genes Dev. 12, 3149-3155[Free Full Text]
15. Kliewer, S. A., Lehmann, J. M., and Willson, T. M. (1999) Science 284, 757-760[Abstract/Free Full Text]
16. Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., and Evans, R. M. (1992) Nature 358, 771-774[CrossRef][Medline] [Order article via Infotrieve]
17. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M. (1995) Cell 83, 835-839[Medline] [Order article via Infotrieve]
18. Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., and Shan, B. (1999) Science 284, 1362-1365[Abstract/Free Full Text]
19. Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., and Lehmann, J. M. (1999) Science 284, 1365-1368[Abstract/Free Full Text]
20. Wang, H., Chen, J., Hollister, K., Sowers, L. C., and Forman, B. M. (1999) Mol. Cell. 3, 543-553[Medline] [Order article via Infotrieve]
21. Laffitte, B. A., Kast, H. R., Nguyen, C. M., Zavacki, A. M., Moore, D. D., and Edwards, P. A. (2000) J. Biol. Chem. 275, 10638-10647[Abstract/Free Full Text]
22. Kanda, T., Foucand, L., Nakamura, Y., Niot, I., Besnard, P., Fujita, M., Sakai, Y., Hatakeyama, K., Ono, T., and Fujii, H. (1998) Biochem. J. 330, 261-265[Medline] [Order article via Infotrieve]
23. Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D. J., and Suchy, F. J. (2001) J. Biol. Chem. 276, 28857-28865[Abstract/Free Full Text]
24. Urizar, N. L., Dowhan, D. H., and Moore, D. D. (2000) J. Biol. Chem. 275, 39313-39317[Abstract/Free Full Text]
25. Kast, H. R., Nguyen, C. M., Sinal, C. J., Jones, S. A., Laffitte, B. A., Reue, K., Gonzalez, F. J., Willson, T. M., and Edwards, P. A. (2001) Mol. Endocrinol. 15, 1720-1728[Abstract/Free Full Text]
26. Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., Maloney, P. R., Willson, T. M., and Kliewer, S. A. (2000) Mol. Cell. 6, 517-526[Medline] [Order article via Infotrieve]
27. Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J., and Mangelsdorf, D. J. (2000) Mol. Cell. 6, 507-515[Medline] [Order article via Infotrieve]
28. Chiang, J. Y. L. (1998) Front Biosci. 3, 176-193
29. Beigneux, A. P., Moser, A. H., Shigenaga, J. K., Grunfeld, C., and Feingold, K. R. (2000) J. Biol. Chem. 275, 16390-16399[Abstract/Free Full Text]
30. Beigneux, A. P., Moser, A. H., Shigenaga, J. K., Grunfeld, C., and Feingold, K. R. (2003) Am. J. Physiol. Endocrinol. Metab. 284, E228-E236[Abstract/Free Full Text]
31. Hartmann, G., Cheung, A. K., and Piquette-Miller, M. (2002) J. Pharmacol. Exp. Ther. 303, 273-281[Abstract/Free Full Text]
32. Jiang, X. C., and Bruce, C. (1995) J. Biol. Chem. 270, 17133-17138[Abstract/Free Full Text]
33. Grunfeld, C., Zhao, C., Fuller, J., Pollack, A., Moser, A., Friedman, J., and Feingold, K. R. (1996) J. Clin. Invest. 97, 2152-2157[Abstract/Free Full Text]
34. Memon, R. A., Fuller, J., Moser, A. H., Smith, P. J., Feingold, K. R., and Grunfeld, C. (1998) Am. J. Physiol. 275, E64-E72[Medline] [Order article via Infotrieve]
35. Neish, A. S., Khachigian, L. M., Park, A., Baichwal, V. R., and Collins, T. (1995) J. Biol. Chem. 270, 28903-28909[Abstract/Free Full Text]
36. Feingold, K. R., Spady, D. K., Pollock, A. S., Moser, A. H., and Grunfeld, C. (1996) J. Lipid Res. 37, 223-228[Abstract]
37. Baumann, H., and Gauldie, J. (1994) Immunol. Today 15, 74-80[CrossRef][Medline] [Order article via Infotrieve]
38. Moshage, H. (1997) J. Pathol. 181, 257-266[CrossRef][Medline] [Order article via Infotrieve]
39. Gabay, C., and Kushner, I. (1999) N. Engl. J. Med. 340, 448-454[Free Full Text]
40. Kolesnick, R., and Golde, D. W. (1994) Cell 77, 325-328[Medline] [Order article via Infotrieve]
41. Kishimoto, T., Taga, T., and Akira, S. (1994) Cell 76, 253-262[Medline] [Order article via Infotrieve]
42. Zhong, Z., Wen, Z., and Darnell, J. E., Jr. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4806-4810[Abstract]
43. Beigneux, A. P., Moser, A. H., Shigenaga, J. K., Grunfeld, C., and Feingold, K. R. (2002) Biochem. Biophys. Res. Commun. 293, 145-149[CrossRef][Medline] [Order article via Infotrieve]
44. Burke, P. A., Drotar, M., Luo, M., Yaffe, M., and Forse, R. A. (1994) Surgery 116, 285-292[Medline] [Order article via Infotrieve]
45. Memon, R. A., Bass, N. M., Moser, A. H., Fuller, J., Appel, R., Grunfeld, C., and Feingold, K. R. (1999) Biochim. Biophys. Acta 1440, 118-126[Medline] [Order article via Infotrieve]
46. Hardardottir, I., Moser, A. H., Fuller, J., Fielding, C., Feingold, K., and Grunfeld, C. (1996) J. Clin. Invest. 97, 2585-2592[Abstract/Free Full Text]
47. Shen, Y., Lookene, A., Nilsson, S., and Olivecrona, G. (2002) J. Biol. Chem. 277, 4334-4342[Abstract/Free Full Text]
48. Fojo, S. S., de Gennes, J. L., Beisiegel, U., Baggio, G., Stalenhoef, A. F., Brunzell, J. D., and Brewer, H. B., Jr. (1991) Adv. Exp. Med. Biol. 285, 329-333[Medline] [Order article via Infotrieve]
49. Crestani, M., Sadeghpour, A., Stroup, D., Galli, G., and Chiang, J. Y. (1998) J. Lipid Res. 39, 2192-2200[Free Full Text]
50. Stroup, D, and Chiang, J. Y. L. (2000) J. Lipid Res. 41, 1-11[Abstract/Free Full Text]
51. Stroup, D, Crestani, M., and Chiang, J. Y. (1997) J. Biol. Chem. 272, 9833-9839[Abstract/Free Full Text]
52. Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A., Oliver, B. B., Su, J. L., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., Spencer, T. A., and Willson, T. M. (1997) J. Biol. Chem. 272, 3137-3140[Abstract/Free Full Text]
53. Chiang, J. Y., Kimmel, R., and Stroup, D. (2001) Gene 262, 257-265[CrossRef][Medline] [Order article via Infotrieve]
54. De Fabiani, E, Mitro, N., Anzulovich, A. C., Pinelli, A., Galli, G., and Crestani, M. (2001) J. Biol. Chem. 276, 30708-30716[Abstract/Free Full Text]
55. Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., and Gonzalez, F. J. (2000) Cell 102, 731-744[Medline] [Order article via Infotrieve]
56. Wang, L, Lee, Y. K., Bundman, D., Han, Y., Thevananther, S., Kim, C. S., Chua, S. S., Wei, P., Heyman, R. A., Karin, M., and Moore, D. D. (2002) Dev. Cell. 2, 721-731[Medline] [Order article via Infotrieve]
57. Kerr, T. A., Saeki, S., Schneider, M., Schaefer, K., Berdy, S., Redder, T., Shan, B., Russell, D. W., and Schwarz, M. (2002) Dev. Cell. 2, 713-720[Medline] [Order article via Infotrieve]
58. Memon, R. A., Moser, A. H., Shigenaga, J. K., Grunfeld, C., and Feingold, K. R. (2001) J. Biol. Chem. 276, 30118-30126[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.